| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 1,738,751 | 1,742,594 | ||
| Research and development | 2,281,174 | 2,050,585 | ||
| Total operating expenses | 4,019,925 | 3,793,179 | ||
| Unrealized gain | 9,494 | -6,004 | ||
| Realized and accrued interest income | 62,266 | 103,245 | ||
| Total other income | 71,760 | 97,241 | ||
| Net loss | -3,948,165 | -3,695,938 | ||
| Earnings per share, basic | -6.71 | - | ||
| Earnings per share, diluted | -6.71 | - | ||
| Weighted average number of shares outstanding, basic | 588,166 | - | ||
| Weighted average number of shares outstanding, diluted | 588,166 | - | ||
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)